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Nuno Sousa, MD, PhD, b,c and Damião Cunha, MD, PhDb,c, On behalf of the group of investigatorsBackground Fabry disease (FD) is a treatable cause of hypertrophic cardiomyopathy (HCM). We aimed to determine
the independent predictors of FD and to define a clinically useful strategy to discriminate FD among HCM.
Methods Multicenter study including 780 patients with the ESC definition of HCM. FD screening was performed by
enzymatic assay in males and genetic testing in females. Multivariate regression analysis identified independent predictors of
FD in HCM. A discriminant function analysis defined a score based on the weighted combination of these predictors.
Results FDwas found in 37of 780patientswithHCM (4.7%): 31with p.F113Lmutation due to a founder effect; and6with other
variants (p.C94S; p.M96V; p.G183V; p.E203X; p.M290I; p.R356Q/p.G360R). FD prevalence in HCM adjusted for the founder
effect was 0.9%. Symmetric HCM (OR 3.464, CI95% 1.151-10.430), basal inferolateral late gadolinium enhancement (LGE) (OR
10.677, CI95% 3.633-31.380), bifascicular block (OR 10.909, CI95% 2.377-50.059) and ST-segment depression (OR 4.401,
CI95% 1.431-13.533) were independent predictors of FD in HCM. The score ID FABRY-HCM [−0.729 + (2.781xBifascicular
block) + (0.590xST depression) + (0.831xSymmetric HCM) + (2.130xbasal inferolateral LGE)] had a negative predictive value of
95.8% for FD, with a cut-off of 1.0, meaning that, in the absence of both bifascicular block and basal inferolateral LGE, FD is a less
probable cause of HCM, being more appropriate to perform HCM gene panel than targeted FD screening.
Conclusion FD prevalence in HCM was 0.9%. Bifascicular block and basal inferolateral LGE were the most powerful
predictors of FD in HCM. In their absence, HCM gene panel is the most appropriate step in etiological study of HCM. (Am Heart J
2020;226:114-26.)Fabry disease (FD) (OMIM 301500) is an X-linked
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other related glycosphingolipids, causing multiorgan
damage. Hypertrophic cardiomyopathy (HCM) is the
main cardiac manifestation of FD, occurring more
commonly in males (43% vs 26%) and nearly one
decade later in females (mean age of onset 39 ± 10 vs
50 ± 11 years).1,
l
s
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Volume 226The prevalence of FD in patients with HCM has widely
varied from 0% to 12% in previous studies (Supplemen-
tary Table I), due to different inclusion criteria, study
designs and screening methods, although the latest
studies, based on larger cohorts of patients and improved
screening methods, have suggested a narrower preva-
lence range of 0% to 4%.2-18 Moreover, the common
finding of genetic variants of unknown significance
(GVUS) in screenings of FD19 mandates that prevalence
results must be continuously re-evaluated as growing
knowledge on Genetics comes to establish the patho-
genic or benign nature of these variants.
FD is a treatable cause of HCM. Enzyme replacement
therapy (ERT) has demonstrated to improve, stabilize or
slow the progression of left ventricular (LV) mass,20-22 wall
thickness,20,21 mid-wall fractional shortening22 and strain21
as well as NYHA class20 and exercise tolerance.21 However,
early diagnosis and treatment are crucial, as the presence of
cardiac fibrosis at the timing of ERT initiation may hamper
long-term improvement of LVmorphology and function and
exercise capacity.21 More recently, migalastat has also
shown to improve LV mass and wall thickness.23
However, despite increasing awareness on the diagnostic
red-flags,24 FD remains a late diagnosis, being the median
delay from symptom onset to diagnosis of 10.5 years (95%
CI: 8-13).25 Therefore, it is essential to accurately
determine independent predictors of FD in patients with
HCM and to create clinically useful tools that could lead to
the early diagnosis of this treatable disease. Herein, we
present the prevalence of FD in patients with HCM in a
large multicenter study. To the best of our knowledge, this
is the first study providing the independent predictors of
FD in a large cohort of patients with HCM and a score to
identify Fabry cases in patients with HCM.Methods
FD screening in patients with HCM
Between January 2008 and March 2018, 780 consecu-
tive patients with HCM were recruited from the
Cardiology consultation of 12 Portuguese hospital centers
(Supplementary Figure 1) and underwent FD screening.
The inclusion criteria were adult patients (≥18 years)
presenting HCM according to the ESC,26 ie, left
ventricular hypertrophy (LVH) with increased LV wall
thickness (≥ 15 mm), by echocardiography, that was not
explained by hypertension, valve disease or other cardiac
overload conditions.
Enzymatic activity of α-galactosidase A was measured in
all patients in dried blood spot (DBS) samples, as
described by Gaspar et al.27 The molecular analysis of
the GLA gene was performed by PCR sequencing of all
exons and their flanking intronic regions, as described by
Shabbeer et al,28 in all females and in males with reduced
α-galactosidase A enzymatic activity (b0.3 nmol/h/spot).Genealogy study
We published in 2013, for the first time, the founder
effect of FD due to the mutation p.F113L in the
Portuguese region of Guimarães, based on genealogy
and haplotype analysis.29 ,30 In this study, we also
performed a genealogy research of all Fabry index
patients that were found with the p.F113L mutation, in
order to confirm the familial connection between them
and a common ancestor. Historians searched for and
analyzed birth, marriage and death certificates, the most
recent in the Citizen Records and the most remote, dating
to the 17th century, in the Parish Records currently filed
in the City Archives.
Predictors of FD in patients with HCM
We collected clinical, electrocardiographic, cardiac
imaging, laboratory and genetic data. Categorical
variables were expressed as percentage. According
to the Kolmogorov-Smirnov test, continuous variables
were all non-normally distributed and therefore
expressed as median with interquartile range (IQR).
Comparison of variables between Fabry and non-Fabry
patients was performed by χ2 test for categorical
variables and Mann-Whitney U test for continuous
variables. Patients with GLA variants of uncertain
clinical significance were excluded from this statisti-
cal analysis. In order to identify independent pre-
dictors of FD among patients with HCM, we performed
a multivariate binary logistic regression analysis,
including the cardiac categorical variables that were
readily available on ECG, echocardiogram and cardiac
MRI and showed statistically significant differences
between FD and non-FD patients. We performed a
Discriminant Function Analysis for FD in patients with
HCM. We used the Wilk's lambda to calculate the
unstandardized coefficients for each of the FD
predictors that have been previously identified by
multivariate regression analysis and then determined a
discriminant score based on the weighted combina-
tion of the independent predictors of FD. We
calculated the mean discriminant scores for Fabry
and non-Fabry patients and determined the best
discriminant cut-off for the score. We used the
maximum likelihood technique to assign each case
to a group according to the specified cut-off, in order
to determine the sensitivity, specificity and positive
and negative predictive values of the score in the
prediction of FD in patients with HCM.
Statistical significance was set at P b .05.
Ethical issues
This research project was approved by the Ethics
Committee of all the hospital centers included in this
study. All patients provided written informed
consent.
Figure 1
Family pedigree of FD patients with the mutation p.F113L, demonstrating a genealogical connection to a common ancestor who was born in 1611
in the Portuguese region of Guimarães. The individuals are coded by generation number in roman numerals-Individual number within the
generation. Males are represented as squares and females as circles. For simplification, only Fabry patients are depicted and respective spouses
were removed from the pedigree. From the 31 p.F113L patients, 27 were found and born in the region of Guimarães, three were found in other
regions but were born b10 km from Guimarães and one was found 375 km from Guimarães. The genealogical connection was found for 23
patients (21 from Guimarães and two that were born near Guimarães). The family connection of the remaining p.F113L patients was not found due
to lack of archive data.
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Prevalence of FD in HCM
The study included 780 patients with HCM, predomi-
nantly males (59.7%), with mean age of 66.0 ± 14.3 years,
22.1% of them with family history of HCM. LVH was
asymmetrical in 65.0% of the cases. Mean interventricular
septum thickness was 17.6 ± 4.3 mm. Mean LV ejection
fraction was 64.4 ± 10.1%. LV outflow tract (LVOT)
obstruction occurred at rest in 28.3%. Cardiac MRI was
performed in 475 patients (60.9%) and revealed LGE in 274
cases (57.7%), mostly intramyocardial (81.5%) and in the
septum (basal (50.0%) and mid (48.2%) antero-septal and
basal (44.9%) and mid (53.6%) infero-septal segments). 24
h-Holter monitoring was performed in 684 patients(87.7%) and detected ventricular tachycardia (VT) in
15.0% (Supplementary Table II). A sarcomere gene panel
had been performed in 497 patients (63.7%). Sarcomeric
variants were found in 124 patients (24.9%), mainly in the
MYBPC3 (11.7%),MYH7 (6.4%), TNNT2 (2.4%) and TPM1
(2.0%) genes. Phenocopies were found in 20 patients
(2.6%): amyloidosis (15 cases), mitochondrial disease (2
cases), PRKAG2 cardiomyopathy (1 case), hemochroma-
tosis (1 case) and sarcoglycanopathy (1 case).
FD was diagnosed in 37 of the 780 patients with HCM
(4.7%). The pathogenic mutation p.F113L was identified
in 31 patients (4.0%) (Supplementary Table III), due to
the founder effect previously documented in the
Portuguese region of Guimarães29 , 30 (Figure 1).



























































F, 50 p.G183V 3.9 / 21.0 76 / n.d. 4.34 9 / 15 98 PW LVH
Non-obstructive
EF 80%





















LGE on inferior and inferoseptal







1.0 / 0 251 / NA 71.1 20 / 15 129 Symmetrical
Non-obstructive
DD grade II














M, 28 p.A143T NA / NA NA / NA NA 23 / 13 209 Asymmetrical
Obstructive
DD grade II
LGE in the basal septal and mid
anteroseptal and inferolateral segments
*Pathogenic mutation on the
MYBPC3 gene (p.R943X)
Non-sustained VT
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*GVUS on MYH7 gene (p.R1781H)
None




LGE in antero-septal segments
None




















F, 83 p.D175E NA / NA NA / NA NA 16 / 10 185 Asymmetrical
Non-obstructive
EF 68%



















α-GAL A, α-galactosidase A; AV, atrioventricular; DD, diastolic dysfunction; EF, ejection fraction; GVUS, genetic variant of unknown significance; IVS, interventricular septum;
LBBB, left bundle branch block; LGE, Late gadolinium enhancement; LV, left ventricular; LVH, left ventricular hypertrophy; NA, non-available; n.d., non-detectable; PW, posterior
wall; RBBB, right bundle branch block; VT, ventricular tachycardia.
Reference values: Enzymatic activity of α-galactosidase A on plasma 6–19 nmol/h/mL, and on leukocytes 36–80 nmol/h/mg; urinary GB3 0.87–13 μg/mmol creatinine;
plasma GB3 0.8–4.52 nmol/mL; plasma Lyso-GB3 0–1.9 ng/mL.
Table I (continued)




Pedigrees of the Fabry families with non-F113L GLA gene variants.
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Volume 226Considering this founder effect, the prevalence of FD in
patients with HCM would be 0.9%.
The other six Fabry patients presented respectively the
following GLA gene variants: p.C94S; p.M96V; p.G183V;
p.E203X; p.M290I; and p.R356Q/p.G360R (Table I).
Lysosomal inclusions were demonstrated in the myocar-
dium of the p.M290I patient and in the skin of the p.
R356Q/p.G360R patient.
Their pedigrees are illustrated in Figure 2. Relevant
family history of these GLA gene variants include: (i) p.
C94S: Affected relatives presented clinical manifestations
compatible with FD (renal failure in one sister; and
proteinuria and acroparesthesias in one daughter, one
niece and one great-niece) and increased plasma lysoGB3;
(ii) p.M96V: The affected 19-year old son presented renal
failure, proteinuria, cornea verticillata, angiokeratomas,
acroparesthesias, hypohidrosis, abdominal pain and
diarrhea as well as increased urinary GB3 (182 μg/mmol
creatinine) and plasma lyso-GB3 (10.82 ng/mL). Skin
biopsy showed lysosomal inclusions compatible with FD;(iii) p.G183V: All her relatives tested negative for this
GLA variant, being impossible to determine if this case
results from a sporadic “de novo” mutation or an
illegitimate father; (iv) p.E203X: All the affected relatives
exhibited a classical phenotype with increased FD
biomarkers; (v): p.M290I: Her two affected sisters have
been so far asymptomatic; (vi) p.R356Q/p.G360R: His
daughter and sister had the same GLA gene variants. The
daughter has been so far asymptomatic and his sister had
HCM and microalbuminuria.
The screening also found two males with residual
enzymatic activity of α-galactosidase A, carrying respec-
tively the p.A143T (0.15 nmol/h/spot) and p.R118C (0.23
nmol/h/spot) variants; two females with the p.R118C
variant; four patients with the p.D313Y variant; an elderly
female with diabetes, hypertension and dyslipidemia, no
family history suggestive of FD and the GVUS p.D175E;
and a female with the novel variants p.V22A/p.A73S, who
presented a pathogenic mutation in the MYBPC3 gene
and in whom pedigree analysis did not support the
Table II. Comparison of baseline characteristics between the patients with HCM secondary to FD vs non-FD
Baseline characteristics Fabry patients (n = 37) Non-Fabry patients (n = 733) P
Male gender (%) 24 (64.9%) 439 (59.9%) .547
Age (years) (median, IQR) 64.0 (57.5, 75.0) 68.0 (57.0, 77.0) .453













































LV outflow tract obstruction at rest (%)
IVS thickness (mm) (median, IQR)
PW thickness (mm) (median, IQR)
LV end-diastolic diameter (mm) (median, IQR)
LV mass (g/m2) (median, IQR)
LV ejection fraction (%) (median, IQR)
Septal Sa (cm/s) (median, IQR)
Lateral Sa (cm/s) (median, IQR)





Septal Ea (cm/s) (median, IQR)
Lateral Ea (cm/s) (median, IQR)























































Cardiac MRI (n = 28 vs 442)
Late gadolinium enhancement (%) 23 (85.2%) 244 (55.8%) .003





Short PR interval (%)
Atrioventricular block (%)
Left bundle branch block (%)
Right bundle branch block (%)
Bifascicular block (%)
T wave inversion (%)
ST segment depression (%)











































Left bundle branch block (%)
















































Diagnostic red-flags for Fabry disease
Stroke (%)
Renal failure (%)
Microalbuminuria N30 mg/24 h (%) (n = 34 vs 295)
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Volume 226pathogenicity of these GLA variants (Table I). In fact, this
p.V22A/p.A73S female had normal enzymatic activity of
alpha-galactosidase A in plasma (9 nmol/h/mL) and mildly
reduced in leukocytes (31 nmol/h/mg). She did not have
children. Her mother also presented HCM as well as the
MYBPC3 mutation, but her GLA status is unclear, as the
HCM genetic testing did not include the GLA gene. Her
brother carried only one of these variants (p.A73S), but
had no clinical manifestations and presented normal
enzymatic activity of alpha-galactosidase A in plasma (10
nmol/h/mL) and leukocytes (37 nmol/h/mg). He also has
no children.Predictors of FD in patients with HCM
Compared to non-Fabry patients, Fabry patients reported
more commonly family history of LVH and complained
more often of dyspnea and pre-syncope. LVH was mainly
symmetrical, with higher posterior wall thickness and
lower LV end-diastolic diameter. LVOT obstruction at rest
was less common. Septal and lateral Sa were lower. LGE
was more common, particularly in the basal and mid
inferolateral segments (63.6% vs 9.6%, P b .001; 54.5% vs
8.1%, P b .001), basal and mid inferior segments (40.9% vs
9.6%, P b .001; 40.9% vs 13.5%, P b .001) and apical lateral,
anterior and septal segments (31.8% vs 13.5%, P = .017;
36.4% vs 18.4%, P = .037; 36.4% vs 19.1% P = .049). Fabry
patients also presented more commonly bifascicular block
and ST-segment depression on ECG and microalbuminuria
and proteinuria (Table II). Of note, nine of the 37 Fabry
patients did not perform cardiac MRI, for the following
reasons: nonconditional pacemaker (n = 2), severe renal
failure (n = 2), nonconditional pacemaker and severe renal
failure (n = 1), other medical device/foreign body incom-
patible with MRI (n = 3) and patient refusal (n = 1).On binary logistic multivariate regression analysis, we
included the cardiac categorical variables that were readily
available from ECG, echocardiogram and cardiac MRI and
showed statistically significant differences between FD and
non-FD patients (Table II): bifascicular block, ST-segment
depression, symmetrical pattern of LVH, LV outflow tract
obstruction at rest and basal inferolateral LGE. The following
variableswere identified as predictors of FD: symmetric LVH
(OR 3.464, CI 95% 1.151-10.430, P = .027), basal inferolat-
eral LGE (OR 10.677, CI 95% 3.633-31.380, P b .001),
bifascicular block (OR 10.909, CI 95% 2.377-50.059, P =
.002) and ST-segment depression on ECG (OR 4.401, CI 95%
1.431-13.533, P = .032). The most powerful predictors
were bifascicular block and basal inferolateral LGE.
Based on the identified predictors of FD, we created the
score ID FABRY-HCM to help to identify FD cases among
patients with HCM:
ID FABRY-HCM = −0.729 + (2.781 x Bifascicular
block on ECG) + (0.590 x ST depression on
ECG) + (0.831 x Symmetric LVH) + (2.130 x basal
inferolateral LGE).
If these variables are present, its respective value in the
score formula will be 1; if they are absent, its value will be
0. In the ID FABRY-HCM score, the cut-off value of 1.0 has
a sensitivity of 63.4%, specificity of 97.2%, positive
predictive value of 68.3% and a negative predictive
value of 95.8%. From the analysis of this score, we can
conclude that neither the presence of symmetrical HCM
or ST-segment depression alone, or the combination of
the two, is enough to obtain a score in favor of FD.
However, the presence of either bifascicular block or
basal inferolateral LGE alone achieves a favorable score
for FD. More importantly, in the absence of both
bifascicular block and basal inferolateral LGE, the
negative predictive value for FD is 95.8%.
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This study found a FD prevalence of 0.9% in patients
with HCM and identified bifascicular block, basal
inferolateral LGE, symmetrical HCM and ST-segment
depression as independent predictors of FD among
patients with HCM. Moreover, this study provides a
score to identify FD cases in patients with HCM.
According to this score, HCM in the absence of both
bifascicular block and basal inferolateral LGE has a
negative predictive value of 95.8% for FD.
Prevalence of FD in HCM
Compared to previous studies on the prevalence of
FD in HCM,2-18 our study presents several strengths: (i)
large sample size; (ii) inclusion of males and females;
(iii) well-defined diagnostic criteria of HCM; (iv)
combined enzymatic and genetic approach as a screen-
ing method; (v) solid evidence of the pathogenicity of
GLA variants that were included for prevalence
calculation.
To the best of our knowledge, this is the second largest
study on the prevalence of FD in HCM.2-18 In previous
studies, inclusion criteria widely ranged (i) from extre-
mely restrictive (patients submitted to myectomy4 or
endomyocardial biopsy5); (ii) to extremely broad (LVH
≥12 mm,16 ≥13 mm,3,6 ,12,13 N13 mm7 or ≥13 mm
without exclusion of hypertension and valve disease2,14);
and (iii) from more elaborated, combining LV thickness
with several factors (no obstruction,15 negative genetic
test for sarcomeric HCM6,9,18 or exclusion of family
history of sudden death in N2 relatives, inheritance
pattern inconsistent with X-linked pattern and histology
compatible with sarcomeric HCM18); (iv) to more
straightforward (ESC definition of HCM8,10,11,17). Like
in these last studies, our study inclusion criteria were
based on the ESC definition of HCM and, therefore, as
described in the literature, LVH was more commonly
asymmetrical with preferential septal involvement and
LGE was more commonly found in the septum. LV
diastolic dysfunction with preserved ejection fraction
was found in most patients. Obstruction at rest (23.8%),
atrial fibrillation (11.7%) and VT (15.0%) were, however,
less frequent than reported in the literature (33.3%, 22.5%
and 25.0%, respectively).26
Someof the previous studies included onlymales and used
enzymatic assay as screening method.2,3,12,13,17 One study
included only females and used electron microscopy of
endomyocardial biopsies as a screening method.5 Other
studies included both genders and used urinary GB3,16
electron microscopy of myectomy specimens,4 the enzy-
matic assay alone,10 the genetic testing6,7 ,9 ,11 or a
combined enzymatic and genetic approach.8,14,15,18 Simi-
larly to these last studies, we includedmales and females and
used a combined enzymatic and genetic approach that
allows FD diagnosis in both genders.31GVUS are commonly found on FD screenings.19 In our
study, most of the reported GLA variants were already
described as pathogenic mutations. The mutation c.337
T N C (p.F113L) leads to enzyme misfolding and con-
sequent degradation in the endoplasmic reticulum,
causing a late-onset phenotype characterized by predo-
minant cardiac involvement.30 The mutation c.281G N C
(p.C94S) affects an enzyme disulfide bond and causes a
severe classical phenotype.32 The mutation c.548G N T
(p.G183V) occurs in a highly conserved residue, buried in
the enzyme 3D structure of the catalytic domain, and is
predicted to cause enzyme instability and a classical
phenotype.33 The mutation c.607G N T (p.E203X) affects
the enzyme active site and causes a classical phenotype of
FD.34 The mutation c.870G N A (p.M290I) leads to
enzyme destabilization and misfolding and was associated
to a classical phenotype.33,35 Our patient presents a
similar missense mutation (c.870G N C), described as
pathogenic in ClinVar database,36 resulting in the same
protein abnormality (p.M290I). The variant c.1067G N A
(p.R356Q) is most likely benign, but the mutation
c.1078G N C (p.G360R) occurs in the enzyme dimer
interface, causing a classical phenotype of FD.37
To the best of our knowledge, theGLA variants p.V22A
and p.A73S were never reported before. According to in-
silico models Polyphen-2 and MutationTaster, p.V22A is
predicted to be a polymorphism, while p.A73S is
predicted to be a disease causing variant.38 ,39 The
variant p.A73E, which affects the same amino acid as p.
A73S, was already reported in a 58-year old female with
LVH, end-stage renal disease and stroke and reduced
enzymatic activity of α-galactosidase A.40 Furthermore,
p.A73V, another variant at the same codon, was
associated to reduced enzymatic activity of α-
galactosidase A in a male newborn.41 However, the
documentation of the p.A73S variant in her brother with
normal enzymatic activity of alpha-galactosidase A on
plasma and leukocytes, together with the finding of a
pathogenic mutation on the MYBPC3 gene, also present
in her mother with HCM, made us classify this HCM as
sarcomeric and this GLA variant as non-disease causing.
To our knowledge, the variant c.286A N G (p.M96V) has
also never been reported, but indisputable evidence of its
pathogenic role was based on the severe classical
phenotype of FD exhibited by the patient and her son,
both with increased urinary GB3 and plasma lyso-GB3,
togetherwith the demonstration of lysosomal inclusions on
skin biopsy.
Patients with the genetic variants p.A143T and p.R118C
were not classified as Fabry patients, as the pathogenic
role of these variants has recently been questioned.42,43
Terryn et al reported p.A143T cases with clinical
manifestations that could be attributable to FD, but
without GB3 deposits in organ biopsies and in which
biopsies revealed alternative diagnoses.42 Recently,
Valtola et al reported elevated plasma lysoGB3 levels
Figure 3
Proposed diagnostic strategy to the identification of Fabry cases during the etiological study of HCM.
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Volume 226and GB3 deposits in p.A143T males with LVH, who had a
relatively high residual enzymatic activity (25%-40%) and
a negative test for an HCM panel with 59 genes,
suggesting that p.A143T is very likely a late-onset FD-
causing variant.44 Nevertheless, our p.A143T patient
presented severe HCM at the age of 28 years old, which is
too young for an HCM due to late-onset FD, even for a
male, which means that even if we considered p.A143T
variant as pathogenic, this variant alone could not explain
HCM at this age neither its severity. Moreover, he had a
documented pathogenic mutation in the MYBPC3 gene
that could fully explain the HCM phenotype. Therefore, we
did not classify this HCM case as caused by FD, although we
cannot exclude a contributing role of thisGLA variant to the
progression of HCM with advancing age.
Besides the relatively high residual enzymatic activity in
leukocytes in p.R118C males (32%-45%), Ferreira et al
reported the case of a 56-year old male with this GLA
variant, who presented mild LVH and myelin figures
within rare cardiomyocytes, but had normal levels of
plasma lyso-Gb3 and urinary GB3 measured at the age of
64 years and no significant progression of the cardiac
disease from the age of 54 to 64 years.43 In our 73-year-old
male with asymmetrical obstructive HCM with LGE in the
septum, it is reasonable to hypothesize that it could be a
sarcomeric HCM, given the pattern of LGE and LVHwhich is more typical of a sarcomeric cause than FD, the
presence of obstruction which is rare in FD and the fact
that the genetic testing, besides revealing a GVUS in the
MYBPC3 gene, included only 11 HCM genes. In our 69-
year old female with apical HCM, although genetic testing
was not performed, a sarcomeric cause is also possible, as
apical HCM is rare in FD. In the 75-year old female with
moderate symmetrical non-obstructive HCM with no
LGE, besides the GVUS on the MYH7 gene, we should
also consider the possibility of isolated basal septal
hypertrophy of the elderly. Although we cannot exclude
that the p.R118C variant may be associated to a very
attenuated and late-onset FD, the unclear role of this GLA
variant and the possibility of alternative diagnoses that
could explain the HCM phenotype in our p.R118C
patients made us exclude these patients from the cohort
of patients classified as FD patients.
The variant p.D313Y is associated with an enzymatic
pseudodeficiency,45 as reflected by the normal plasma
lyso-Gb3 values both in our female and male patients, and
therefore not included in FD prevalence calculation.
HCM genetic testing would be appropriate to assess a
sarcomeric cause in the 36-year old male with asymme-
trical non-obstructive HCM and antero-septal LGE, and in
the 70-year old female with asymmetrical non-obstructive
HCM and no LGE, despite the absence of a family history
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testing would also be appropriate to assess a sarcomeric
or PRKAG2 cause in the 70-year old female with this GLA
variant and symmetrical obstructive HCM, short PR
interval, left bundle branch block, family history of
HCM and no history of hypertension. It should be
considered the possibility of isolated basal septal hyper-
trophy of the elderly in the 76-year old female with the p.
D313Y variant and moderate symmetrical non-
obstructive LVH, no LGE and no family history of HCM.
Finally, the variant p.D175E, predicted by Polyphen-2 as
benign, was already described in a female with normal lyso-
GB3 and in-vitro near-normal enzymatic activity.33 In our
patient, sarcomeric HCM and isolated basal septal hyper-
trophy cannot be fully excluded as causes of LVH, and
proteinuria, renal failure and stroke could also be explained
by the cardiovascular risk factors. Therefore, we considered
p.D175E as a GVUS, probably benign.
Based on these considerations and the founder effect of
FD due to the p.F113L mutation in the region of
Guimarães,29,30 FD prevalence in HCM was set at 0.9%.
If we considered p.A143T and p.R118C variants to be
associated with attenuated and late-onset FD, FD pre-
valence in HCM would be 1.4% (11/780).
Predictors of FD in patients with HCM
FD is a treatable condition and cardiologists' awareness
is paramount to achieve an appropriate and timely
diagnosis and treatment.
In this study, the most powerful predictors of FD among
HCM patients were bifascicular block and basal inferolat-
eral LGE. The LVH pattern is readily known as soon as the
diagnosis of HCM is established and, therefore, is one of the
first characteristics that will guide the etiological study of
HCM. Although HCM is typically symmetrical in FD,24 the
common occurrence of fibrosis and thinning of the
posterior wall with loss of the symmetrical LVH pattern
at the HCM stage (≥15 mm)24,46 make, together with the
existence of this LVH pattern in other phenocopies
(amyloidosis, mitochondrial disorders, Danon disease),24
symmetrical HCM a weak predictor of FD, as was
demonstrated in this study. Conversely, although basal
inferolateral LGE may appear in other conditions47,48 and
LGE may involve other segments with FD progression,49
the basal inferolateral LGE revealed to be one of the most
powerful predictors of FD. Niemann et al also found that
when ST segment or T wave alterations are absent,
replacement fibrosis is very unlikely in FD, which might
explain the finding of ST depression as a predictor of FD in
HCM.50 Cardiac conduction disorders are known cardiac
manifestations of FD.1 However, to our knowledge, this is
the first study demonstrating that bifascicular block is the
most powerful predictor of FD in patients with HCM.
Although extracardiac manifestations, such as acropar-
esthesias, angiokeratomas and cornea verticillata, are
red-flags to FD diagnosis,24 they are not commonlysearched by cardiologists during the diagnostic study of
HCM. Besides, they are frequently absent in heterozygous
females and late-onset phenotypes.1 Renal or cerebrovas-
cular disease may also be absent in heterozygous females
and in some late-onset phenotypes with a predominant
organ involvement,1 which limits their utility in the
etiological study of HCM. Conversely, a score to guide the
suspicion of FD based on LVH characteristics that are
readily available on ECG, echocardiogram and cardiac
MRI appeared to be useful in the clinical practice.
However, from the analysis of the score, it became
clear that its application was not needed in the clinical
practice and that the algorithm to define the most
appropriate diagnostic strategy in the etiological study of
HCM could be simplified as illustrated in Figure 3. In
simple words, in the presence of either bifascicular block
or basal inferolateral LGE, targeted FD screening is the
most appropriate next step in the etiological study of
HCM; and in the absence of both bifascicular block and
basal inferolateral LGE, FD is a less probable cause of
HCM and a wide HCM gene panel is the most adequate
strategy to its etiological study. The positive predictive
value of the score (68.3%) is explained by the low
prevalence of FD. However, given the cost difference
between a targeted FD screening and a wider HCM gene
panel, especially in males, it seems reasonable to proceed
first with a targeted FD screening in patients with positive
scores, i.e., with bifascicular block and/or basal infer-
olateral LGE, despite the modest positive predictive
value. The score sensitivity is 63.4%, which might be
explained by the fact that bifascicular block already
represent an advanced stage of the disease that may be
absent in the milder cases of FD at the HCM stage (≥15
mm). Although less probable, the basal inferolateral LGE
may also be absent in these milder cases of Fabry HCM.
Moreover, the high negative predictive value for FD
(95.8%) that is achieved in patients with HCM in the
absence of both bifascicular block and basal inferolateral
LGE is known to be less meaningful in the field of rare
diseases, as even a low number of false negatives may
represent a non-negligible percentage of missed diag-
noses in a universe of rare cases.
However, although the score will miss milder Fabry HCM
cases and thesemay represent a non-negligible percentageof
FD cases, it is important to emphasize that this algorithm
does not intend to limit FD screening in patients with
negative scores, i.e. without bifascicular block and basal
inferolateral LGE, rather it intends to guide physicians on the
most probable cause of HCM and therefore the most
appropriate next step in the etiological study of HCM. Given
the potential clinical impact of specific FD therapy, it is
advisable to systematically screen all patients with unex-
plained LVH for FD, either by targeted screening or within a
wider genetic approach. However, targeted FD screening
has a lower cost than a wider gene panel of HCM. In the
presence of bifascicular block or basal inferolateral LGE, this
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the absence of both bifascicular block and basal inferolateral
LGE, it favors awider panel of HCM genes that currently also
include theGLA gene, despite the lower probability of FD in
this case (Figure 3). Our study presents some limitations that
should be acquainted. The diagnosis of FD was considered
according to the current knowledge on genetics that is
constantly evolving and may reveal in the future different
pathophysiological roles for theGLA gene variants that were
found in this study. Themajority of the Fabry casespresented
the sameGLA genemutation. This score only applies to adult
patients with the ESC definition of HCM and therefore is not
applicable to pediatric patients or patients with milder LVH
(wall thickness b15mm), in whom the early diagnosis of FD
could potentially carry a higher prognostic impact. Never-
theless, it should be emphasized that the identification of
Fabry cases at the HCM stage could enable the identification
of several relatives51 at earlier stages of the disease. Finally,
future studies are needed to obtain an external validation of
this score in other large cohorts of HCM and in patients with
other GLA gene mutations.
In summary, this study, based on the ESC definition of
HCM, using a combined enzymatic and genetic approach
and taking into account the current knowledge on
genetics of FD and the existence of a founder effect in
a particular Portuguese region, sets FD prevalence among
patients with HCM in 0.9%. This study also showed that
bifascicular block and basal inferolateral LGE are the most
powerful predictors of FD in patients with HCM. In the
absence of both bifascicular block and basal inferolateral
LGE, FD is a less probable cause of HCM, according to the
ID FABRY-HCM score, being more appropriate to per-
form an HCM gene panel as the next step of the
etiological study of HCM.
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